Condition: Cancer of Rectum · Sponsor: Vejle Hospital
In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy. Prospective trials, including the previous Danish Watchful Waiting trials (NCT00952926, NCT02438839) in early rectal cancer have demonstrated high levels of organ preservation with dose-escalation, but it is unclear whether this was primarily due to tumor stage or dose level. The aim of the present study is to investigate if a higher dose of radiotherapy is superior compared to a standard dose in patients with early rectal cancer undergoing chemoradiotherapy with curative intent.
This description comes directly from the study's public registry record.
Lars H Jensen, MD, PhD · +45 7940 6802 · lars.henrik.jensen@rsyd.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Recruiting |
| Copenhagen University Hospital, Righshospitalet and Bispebjerg Hospital | Copenhagen, Denmark | Recruiting |
| Zealand University Hospital, Næstved | Næstved, Denmark | Recruiting |
| Zealand University Hospital, Roskilde | Roskilde, Denmark | Recruiting |
| Department of Oncology, Vejle Hospital | Vejle, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04095299